Provectus Biopharmaceuticals Stock Performance
| PVCT Stock | USD 0.06 0.01 7.69% |
The company holds a Beta of -0.31, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Provectus Biopharmaceutica are expected to decrease at a much lower rate. During the bear market, Provectus Biopharmaceutica is likely to outperform the market. At this point, Provectus Biopharmaceutica has a negative expected return of -0.43%. Please make sure to check Provectus Biopharmaceutica's value at risk and the relationship between the skewness and relative strength index , to decide if Provectus Biopharmaceutica performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Provectus Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in January 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Provectus |
Provectus Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 8.90 in Provectus Biopharmaceuticals on September 30, 2025 and sell it today you would lose (2.90) from holding Provectus Biopharmaceuticals or give up 32.58% of portfolio value over 90 days. Provectus Biopharmaceuticals is currently does not generate positive expected returns and assumes 6.1941% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of otc stocks are less volatile than Provectus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Provectus Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Provectus Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Provectus Biopharmaceuticals, and traders can use it to determine the average amount a Provectus Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0701
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PVCT |
Based on monthly moving average Provectus Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Provectus Biopharmaceutica by adding Provectus Biopharmaceutica to a well-diversified portfolio.
Provectus Biopharmaceutica Fundamentals Growth
Provectus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Provectus Biopharmaceutica, and Provectus Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Provectus OTC Stock performance.
| Return On Asset | -1.85 | |||
| Operating Margin | (4.77) % | |||
| Current Valuation | 46.73 M | |||
| Shares Outstanding | 419.55 M | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 5.44 X | |||
| Price To Sales | 55.94 X | |||
| EBITDA | (4.56 M) | |||
| Cash And Equivalents | 84.27 K | |||
| Total Debt | 2.29 M | |||
| Debt To Equity | 0.25 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.01 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 3.51 M | |||
| Retained Earnings | (180.8 M) | |||
| Current Asset | 14.72 M | |||
| Current Liabilities | 4.12 M | |||
About Provectus Biopharmaceutica Performance
Assessing Provectus Biopharmaceutica's fundamental ratios provides investors with valuable insights into Provectus Biopharmaceutica's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Provectus Biopharmaceutica is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Provectus Biopharmaceutica performance evaluation
Checking the ongoing alerts about Provectus Biopharmaceutica for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Provectus Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Provectus Biopharmaceutica generated a negative expected return over the last 90 days | |
| Provectus Biopharmaceutica has high historical volatility and very poor performance | |
| Provectus Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Provectus Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Provectus Biopharmaceuticals currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Provectus Biopharmaceuticals currently holds about 84.27 K in cash with (1.01 M) of positive cash flow from operations. |
- Analyzing Provectus Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Provectus Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Provectus Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Provectus Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Provectus Biopharmaceutica's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Provectus Biopharmaceutica's otc stock. These opinions can provide insight into Provectus Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Provectus OTC Stock Analysis
When running Provectus Biopharmaceutica's price analysis, check to measure Provectus Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Provectus Biopharmaceutica is operating at the current time. Most of Provectus Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Provectus Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Provectus Biopharmaceutica's price. Additionally, you may evaluate how the addition of Provectus Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.